J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESSDAI at week 24 vs placebo. Nipocalimab is an investigational anti-FcRn treatment being studied in RA, & myasthenia gravis https://t.co/L7WNtdii8N https://t.co/Ro6UoPT2fR
Links:
Johnson & Johnson reports results for nipocalimab from a Phase 3 study in gener…
https://bit.ly/3Ozf6M5
Feb-08-2024
